SCHEMBL5128237

SCHEMBL5128237

Cc1csc2nc(-n3cccn3)nc(NCCc3ccc4c(c3)OCO4)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 1/20 0.41
NOS2 P35228 3/20 0.39
HTT P42858 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE5A O76074 1/20 0.37
NOS1 P29475 1/20 0.36
FLT1 P17948 3/20 0.36
KDR P35968 3/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
IDO1 P14902 1/20 0.35
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129101 0.91 ALDH1A1 (0.46) HTTALDH1A1TSHRNPSR1KMT2A
SCHEMBL5128236 0.86 SMN1; SMN2 (0.41) BCDIN3DNOS2HTTALDH1A1MAPT
SCHEMBL5124266 0.86 BCDIN3D (0.42) BCDIN3DNOS2HTTALDH1A1TSHR
SCHEMBL5128242 0.86 ALDH1A1 (0.42) HTTALDH1A1TSHRNPSR1KMT2A
SCHEMBL5122969 0.85 NOS2 (0.54) NOS2NOS1
SCHEMBL5128977 0.85 BCDIN3D (0.40) BCDIN3DNOS2HTTALDH1A1NPSR1
SCHEMBL5122226 0.84 BCDIN3D (0.39) BCDIN3DNOS2HTTALDH1A1TSHR
SCHEMBL5118165 0.83 BCDIN3D (0.45) BCDIN3DNOS2ALDH1A1TSHRNPSR1
SCHEMBL7619052 0.83 BCDIN3D (0.44) BCDIN3DNOS2HTTALDH1A1NPSR1
SCHEMBL5781513 0.83 ALDH1A1 (0.44) HTTALDH1A1TSHRNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 BCDIN3D 1161/4885NOS2 724/4885HTT 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.